Moody National Bank Trust Division Reduces Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Moody National Bank Trust Division reduced its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,769 shares of the medical equipment provider’s stock after selling 915 shares during the period. Moody National Bank Trust Division’s holdings in Lantheus were worth $1,321,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Wilmington Savings Fund Society FSB purchased a new position in Lantheus in the third quarter valued at about $25,000. Signaturefd LLC boosted its stake in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares during the last quarter. Nkcfo LLC acquired a new stake in shares of Lantheus during the second quarter worth approximately $47,000. UMB Bank n.a. increased its stake in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after buying an additional 126 shares during the last quarter. Finally, Kathleen S. Wright Associates Inc. acquired a new stake in Lantheus in the third quarter valued at $51,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $94.65 on Tuesday. The firm has a market capitalization of $6.58 billion, a PE ratio of 15.75 and a beta of 0.46. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89. The business’s fifty day moving average price is $90.39 and its two-hundred day moving average price is $99.69.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. JMP Securities lowered their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday, November 7th. The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. Finally, Truist Financial reiterated a “buy” rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and an average price target of $131.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.